To access this material please log in or register

Register Authorize

Report of the Expert Council “Role of Omacor in current cardiology”

Arutyunov G. P., Rupp H., Karpov Yu. A., Lopatin Yu. M., Moiseev V. S.

Keywords: treatment, omega-3 fatty acids, cardiovascular pathology

DOI: 10.18087/rhj.2013.4.1866

  1. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med. 2011;364 (25):2439–2450.
  2. Leaf A, Xiao YF, Kang JX, Billman GE. Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias. J Membr Biol. 2005;206 (2):129–139.
  3. Oh DY, Talukdar S, Bae EJ et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensiti­zing effects. Cell. 2010;142 (5):687–698.
  4. Calder P. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75 (3):645–662.
  5. Cawood AL, Ding R, Napper FL et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorpo­rated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212 (1):252–259.
  6. Rupp H, Rupp TP, Alter P, Maisch B. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart. 2010;96 (8):595–598.
  7. Rupp H, Rupp TP, Alter P, Maisch B. Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsa­turated fatty acids by structural heart disease resulting in «HUFA deficiency». Can J Physiol Pharmacol. 2012;90 (1):55–73.
  8. Albert CM, Campos H, Stamfer MJ et al. Blood levels of long chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002;346 (15):1113–1118.
  9. Nodari S, Triggiani M, Campia U et al. Effects of n-3 polyunsatura­ted fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57 (7):870–879.
  10. Macchia A, Levantesi G, Franzosi MG et al, for the GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005;7 (5):904–909.
  11. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354 (9177):447–455.
  12. Marchioli R, Barzi F, Bomba E. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) – Prevenzione. Circulation. 2002;105 (16):1897–1903.
  13. Tavazzi L, Maggioni AP, Marchioli R. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9645):1223–1230.
  14. The ORIGIN trial investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. N Engl J Med. 2012;367 (4):309–318.
  15. Mozaffarian D, Marchioli R, Macchia A et al. Fish oil and post­operative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA. 2012;308 (19):2001–2011.
  16. Rauch B, Schiele R. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122 (21):2152–2159.
  17. Bianconi L, Calò L, Mennuni M et al. n-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace. 2011;13 (2):174–181.
  18. Nodari S, Triggiani M, Campia U et al. n-3 Polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: A prospective, randomized study. Circulation. 2011;124 (10):1100–1106.
  19. Моисеев С. В. n-3 Полиненасыщенные жирные кислоты: о чем свидетельствуют результаты последних мета-анализов? Клин. фармакол. тер. 2013;22 (1):23–28.
  20. Rizos EC, Ntzani EE, Bika E et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308 (10):1024–1033.
  21. Xin W, Wei W, Li X. Effects of fish oil supplementation on cardiacfunction in chronic heart failure. A meta-analysis of randomised controlled trials. Heart. 2012;98 (22):1620–1625.
  22. Gissi-Hf Investigators. Effect of rosuvastatin in patients with chro­nic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372 (9645):1231–1239.
  23. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin i in older patients with systolic heart failure. N Engl J Med. 2007;357 (22):2248–2261.
  24. Poole CD, Halcox JP, Jenkins-Jones S et al. Omega-3 fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: A retrospective, matched-cohort study. Clin Ther. 2013;35 (1):40–51
Arutyunov G. P., Rupp H., Karpov Yu. A. et al. Report of the Expert Council “Role of Omacor in current cardiology”. Russian Heart Journal. 2013;12(4):259-264

To access this material please log in or register

Register Authorize
Ru En